Sirolimus-Eluting Stents Remain Superior to Bare-Metal Stents at Two Years
Medium-Term Results From the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry
Andrew T.L. Ong, MBBS, FRACP,
Ron T. van Domburg, PhD,
Jiro Aoki, MD,
Karel Sonnenschein,
Pedro A. Lemos, MD, PhD and
Patrick W. Serruys, MD, PhD, FACC*
Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
View larger version (17K):
[in a new window]
|
Figure 1 Two-year adverse events in patients treated with bare stents before the introduction of sirolimus-eluting stents (SES) (pre-SES group) and in patients treated exclusively with SES implantation (SES group). (A) Cumulative risk of death. (B) Death or myocardial infarction. (C) Death, myocardial infarction, or target vessel revascularization.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Two-year cumulative risk of target vessel revascularization in patients treated with bare stents before the introduction of sirolimus-eluting stents (SES) (pre-SES group) and in patients treated exclusively with SES implantation (SES group).
|
|
|
